Stockreport

Entrada Therapeutics Reports Second Quarter 2024 Financial Results

Entrada Therapeutics, Inc.  (TRDA) 
PDF – Generated positive data from the Phase 1 clinical trial of ENTR-601-44 for DMD, including dose-dependent plasma and muscle concentration, and exon skipping – – Planni [Read more]